scholarly journals Stability of Tumor Markers CA 19.9, CA 125, and CA 15.3 in Serum Obtained from Plain Tubes and Tubes Containing Thixotropic Gel Separator

1997 ◽  
Vol 43 (12) ◽  
pp. 2430-2431 ◽  
Author(s):  
Giuseppe Banfi ◽  
Pierangela Parma ◽  
Marina Pontillo
Keyword(s):  
Tumor Markers ◽  
Ca 125 ◽  
Ca 15.3 ◽  
Ca 19.9

scholarly journals Serum Tumor Markers may Precede Instrumental Response to Chemotherapy in Patients with Metastatic Cancer

2003 ◽  
Vol 18 (4) ◽  
pp. 295-300 ◽  
Author(s):  
C. Massacesi ◽  
M.B.L. Rocchi ◽  
F. Marcucci ◽  
A. Pilone ◽  
M. Galeazzi ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Tumor Markers ◽  
Clinical Benefit ◽  
Instrumental Response ◽  
Metastatic Cancer ◽  
Ca 125 ◽  
Ca 15.3 ◽  
Serum Tumor Markers ◽  
Ca 19.9 ◽  
Pain Improvement

Purpose Although serum tumor markers (STMs) are widely used in clinical practice, their predictive role for the response to anticancer treatment is still controversial. The correlation of CEA, CA 15.3, CA 19.9, CA 125 (only with peritoneal involvement) and NSE levels with imaging response and clinical benefit was investigated in 60 non-selected patients with metastatic epithelial cancers treated by single-agent docetaxel chemotherapy. Methods STM measurement was performed at baseline and subsequently every three to four weeks. We applied the WHO criteria to evaluate both STM and instrumental responses. Concordance analysis was performed by the Cohen Kw index, and the significance of the results was established using the Fleiss, Cohen & Everitt test. Qualitative interpretation of data was obtained with the Landis & Koch scale. Correlations of STM response with clinical benefit (PS or pain improvement) were evaluated by the chi-square test. Results The primary tumors included breast cancers (38 patients), gastrointestinal non-colorectal cancers (12 patients), and lung cancers (10 patients). An overall significant good degree of agreement was observed between STM and instrumental response (p<0.0005). The degree of agreement for each marker was as follows: excellent for CEA (p<0.0005) and CA 125 (p=0.006), good for CA 15.3 (p<0.0005) and CA 19.9 (p=0.011). Restricted analysis for the correlation of each marker with primary tumor origin showed good prediction of radiological response for CA 15.3 and CEA in breast cancer patients (p<0.0005 for both), for CEA and CA 19.9 in gastrointestinal cancer patients (p=0.01 and 0.04, respectively), and for CEA+NSE in lung cancer patients (p=0.01). Conversely, STM response did not correlate significantly with the clinical benefit for the patients, both in terms of PS and pain improvement (p=0.24 and p=0.42, respectively). Conclusion This study showed STMs to be good predictors of tumor response. Although STMs cannot replace diagnostic imaging, in metastatic cancer they might be useful to optimize the timing of radiological re-evaluation in the palliative setting.

scholarly journals Valor diagnóstico de la combinación de nueve marcadores tumorales en neoplasias

2017 ◽  
Vol 1 (1) ◽  
pp. 19
Author(s):  
Ivón Howland Álvarez ◽  
Yolanda Cruz Gómez ◽  
Nairobi Fonseca Torres ◽  
Bárbara Dinorah Hidalgo Martínez ◽  
Viorkis Pérez Ortiz ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Predictive Value ◽  
Clinical Laboratory ◽  
Reference Value ◽  
Ca 125 ◽  
Cytokeratin 19 ◽  
Neoplastic Disease ◽  
Ca 15.3 ◽  
Ca 19.9 ◽  
Marcadores Tumorales

Muchos  marcadores  tumorales  (MT)  no  son  específicos  a  un  tipo  particular  de  cáncer  y  el  nivel de uno de ellos puede aumentar como consecuencia de más de un tipo de cáncer, por lo que se utilizan en combinación para lograr mayor efectividad diagnóstica. Este trabajo se propone evaluar el valor diagnóstico de la combinación de nueve MT utilizados en diagnóstico de neoplasia tanto de forma individual como combinados. Se realizó un estudio retrospectivo entre enero 2013 y mayo de 2015 en el Laboratorio Clínico del Centro de Investigaciones Médico Quirúrgicas de La Habana a  100  pacientes  con  diagnóstico  de  cáncer  o  sospecha  clínica  de  neoplasia  oculta  a  quienes  se les  determinaron  los  marcadores  tumorales:  antígeno  carbohidrato  (CA)  19.9,  CA  72.4,  CA  125, CA  15.3,  antígeno  carcinoembrionario  (CEA),  componente  de  la  citoqueratina  19  (Cyfra  21-1), gonadotropina coriónica (HCG), ferritina y antígeno prostático de superficie (PSA). En todos los MT se observó un incremento del valor de corte sobre el valor límite superior de referencia mayor al 8%. En conjunto, la sensibilidad, especificidad, valor predictivo positivo (VPP) y valor predictivo negativo fueron de 23%, 99%, 96% y 51%, respectivamente. Para un valor de corte de 50 la especificidad y el VPP aumentaron a 99,6% y 97,5%, respectivamente. El uso de los 9 marcadores tumorales en conjunto mostró ser útil en el proceso de diagnóstico de pacientes con enfermedad neoplásica.  Palabras  clave:  marcadores  tumorales,  CA  19.9,  CA  72.4,  CA  125,  CA  15.3,  CEA,  Cyfra  21-1, HCG, Ferritina y PSA Abstract: Many  tumor  markers  are  not  specific  to  a  particular  type  of  cancer  and  the  level  of  one  of  them may increase as a result of more than one type of cancer, that’s why they are used in combination to achieve greater diagnostic effectiveness. This work aims to evaluate the diagnostic value of the combination of nine tumor markers commonly used in diagnosis of neoplasia both individually and in combination. A retrospective study from January 2013 to May 2015 was conducted at the Clinical Laboratory of the Center for Medical and Surgical Research in Havana, in 100 patients with cancer diagnosis or clinical suspicion of occult malignancy and to whom carbohydrate antigen (CA) 19.9, 72.4,  CA  125,  CA  15.3,  carcinoembryonic  antigen  (CEA),  component  cytokeratin  19  (CYFRA  21-1), chorionic gonadotropin (HCG), ferritin and prostate surface antigen (PSA) tumor markers were identified. An increase of cutoff value above the upper limit reference value in all higher TM 8% was observed. Overall, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value were 23 %, 99 %, 96 % and 51 %, respectively. For a cut value of 50 specificity and PPV, they increased to 99.6% and 97.5%, respectively. The use of 9 tumor markers together showed to be useful in the process of diagnosing patients with neoplastic disease. Key words: tumor markers, CA 19.9, CA 72.4, CA 125, CA 15.3, CEA, Cyfra 21-1, HCG, Ferritina and PSA.

scholarly journals Valor diagnóstico de la combinación de nueve marcadores tumorales en neoplasias

2017 ◽  
Vol 1 (1) ◽  
pp. 19
Author(s):  
Ivón Howland Álvarez ◽  
Yolanda Cruz Gómez ◽  
Nairobi Fonseca Torres ◽  
Bárbara Dinorah Hidalgo Martínez ◽  
Viorkis Pérez Ortiz ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Predictive Value ◽  
Clinical Laboratory ◽  
Reference Value ◽  
Ca 125 ◽  
Cytokeratin 19 ◽  
Neoplastic Disease ◽  
Ca 15.3 ◽  
Ca 19.9 ◽  
Marcadores Tumorales

Muchos  marcadores  tumorales  (MT)  no  son  específicos  a  un  tipo  particular  de  cáncer  y  el  nivel de uno de ellos puede aumentar como consecuencia de más de un tipo de cáncer, por lo que se utilizan en combinación para lograr mayor efectividad diagnóstica. Este trabajo se propone evaluar el valor diagnóstico de la combinación de nueve MT utilizados en diagnóstico de neoplasia tanto de forma individual como combinados. Se realizó un estudio retrospectivo entre enero 2013 y mayo de 2015 en el Laboratorio Clínico del Centro de Investigaciones Médico Quirúrgicas de La Habana a  100  pacientes  con  diagnóstico  de  cáncer  o  sospecha  clínica  de  neoplasia  oculta  a  quienes  se les  determinaron  los  marcadores  tumorales:  antígeno  carbohidrato  (CA)  19.9,  CA  72.4,  CA  125, CA  15.3,  antígeno  carcinoembrionario  (CEA),  componente  de  la  citoqueratina  19  (Cyfra  21-1), gonadotropina coriónica (HCG), ferritina y antígeno prostático de superficie (PSA). En todos los MT se observó un incremento del valor de corte sobre el valor límite superior de referencia mayor al 8%. En conjunto, la sensibilidad, especificidad, valor predictivo positivo (VPP) y valor predictivo negativo fueron de 23%, 99%, 96% y 51%, respectivamente. Para un valor de corte de 50 la especificidad y el VPP aumentaron a 99,6% y 97,5%, respectivamente. El uso de los 9 marcadores tumorales en conjunto mostró ser útil en el proceso de diagnóstico de pacientes con enfermedad neoplásica.  Palabras  clave:  marcadores  tumorales,  CA  19.9,  CA  72.4,  CA  125,  CA  15.3,  CEA,  Cyfra  21-1, HCG, Ferritina y PSA Abstract: Many  tumor  markers  are  not  specific  to  a  particular  type  of  cancer  and  the  level  of  one  of  them may increase as a result of more than one type of cancer, that’s why they are used in combination to achieve greater diagnostic effectiveness. This work aims to evaluate the diagnostic value of the combination of nine tumor markers commonly used in diagnosis of neoplasia both individually and in combination. A retrospective study from January 2013 to May 2015 was conducted at the Clinical Laboratory of the Center for Medical and Surgical Research in Havana, in 100 patients with cancer diagnosis or clinical suspicion of occult malignancy and to whom carbohydrate antigen (CA) 19.9, 72.4,  CA  125,  CA  15.3,  carcinoembryonic  antigen  (CEA),  component  cytokeratin  19  (CYFRA  21-1), chorionic gonadotropin (HCG), ferritin and prostate surface antigen (PSA) tumor markers were identified. An increase of cutoff value above the upper limit reference value in all higher TM 8% was observed. Overall, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value were 23 %, 99 %, 96 % and 51 %, respectively. For a cut value of 50 specificity and PPV, they increased to 99.6% and 97.5%, respectively. The use of 9 tumor markers together showed to be useful in the process of diagnosing patients with neoplastic disease. Key words: tumor markers, CA 19.9, CA 72.4, CA 125, CA 15.3, CEA, Cyfra 21-1, HCG, Ferritina and PSA.

Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE

Tumor Biology ◽  
2008 ◽  
Vol 29 (6) ◽  
pp. 371-380 ◽  
Author(s):  
Rafael Molina ◽  
Jose Maria Auge ◽  
Jose Miguel Escudero ◽  
Ramon Marrades ◽  
Nuria Vi&ntilde;olas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Markers ◽  
Ca 125 ◽  
Ca 15.3 ◽  
Ca 19.9

Analytical Performance of Ca 19.9, Ca 125 and Ca 15.3 Assays as Observed through an External Quality Assessment Program

1994 ◽  
Vol 9 (1) ◽  
pp. 43-47 ◽  
Author(s):  
G.C. Zucchelli ◽  
A. Pilo ◽  
M.R. Chiesa ◽  
S. Masini ◽  
A. Clerico
Keyword(s):  
Monoclonal Antibody ◽  
Quality Control ◽  
Quality Assessment ◽  
External Quality Assessment ◽  
Ca 125 ◽  
External Quality ◽  
Ca 15.3 ◽  
Assessment Program ◽  
Ca 19.9 ◽  
Control Samples

Immunoassays of the tumor markers CA 19.9, CA125 and CA 15.3 are generally acknowledged to be a useful tool in the management of cancer patients. As a consequence, many methods developed by different companies are now commercially available. However, discrepancies have been described in the results of marker determinations even when the same monoclonal antibody was used. An external quality assessment (EQA) was carried out; starting from 1989 about 110 laboratories participated; since December 1991 the program was linked with the interlaboratory program Oncocheck organized by the Service de Radiopharmacie et Radioanalyse, University of Lyon. At present more than 200 laboratories of many European countries are involved: cumulatively 47 quality control samples have been prepared and sent to the participants. This manuscript is a report on data collected for CA 19.9, CA 125, and CA 15.3.

scholarly journals Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Rosekeila Simões Nomelini ◽  
Taísa Morete da Silva ◽  
Beatriz Martins Tavares Murta ◽  
Eddie Fernando Candido Murta
Keyword(s):  
Tumor Markers ◽  
Blood Count ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Borderline Ovarian Tumor ◽  
Tumor Type ◽  
Borderline Ovarian Tumors ◽  
Stage Ib ◽  
Ca 19.9 ◽  
Stage Ia

The aim of this paper was to evaluate the parameters of blood count and tumor markers in borderline ovarian tumors. We evaluated 21 patients who had confirmed histopathologic diagnosis of borderline ovarian tumor. We recorded age, parity, tumor type, stage of cancer, serum levels of tumor markers (CA-125, CA-15.3, CA-19.9, CEA, AFP), and the parameters of blood count, fasting glucose, disease-free survival and overall. The patients were divided into two groups, stage IA (n=13) and stage IB-IIIC (n=8). The unpaired t-test and Fisher's exact test were used, with P values of less than 0.05 being considered to indicate statistical significance. Levels of red blood cells, hematocrit, and hemoglobin were significantly higher in stage IA when compared with stage IB-IIIC (P<0.05). The levels of tumor marker CEA had a tendency to be higher in the group stage IB-IIIC (0.08). Abnormal levels of CEA and CA-19.9 were found more frequently in stages IB-IIIC. Therefore, parameters of blood count, CEA, and CA-19.9 should be targeted for further research in identifying prognostic factors in borderline tumors.

scholarly journals R-157. Serum CEA, CA-125, CA-15.3 and CA-19.9 levels as a diagnostic test for endometriosis

1999 ◽  
Vol 14 (Suppl_3) ◽  
pp. 349-349
Author(s):  
G. Pados ◽  
D. Hatzis ◽  
T. Timpanidis ◽  
K. Paulitou ◽  
S. Hrisohoidou ◽  
...  
Keyword(s):  
Diagnostic Test ◽  
Ca 125 ◽  
Ca 15.3 ◽  
Ca 19.9 ◽  
Serum Cea

Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients

2005 ◽  
Vol 46 (10) ◽  
pp. 1471-1476 ◽  
Author(s):  
Montserrat Batlle ◽  
Josep-Maria Ribera ◽  
Albert Oriol ◽  
Cruz Pastor ◽  
José-Luis Mate ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ca 125 ◽  
Ca 15.3 ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Tumor markers in heart failure

2016 ◽  
Vol 11 (1) ◽  
pp. 18-20
Author(s):  
Nicolae BACALBASA ◽  
◽  
Alexandra GIREADA ◽  
Irina BALESCU ◽  
Cristian BALALAU ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Literature Review ◽  
Tumor Markers ◽  
Serum Levels ◽  
Ca 125 ◽  
Inflammation Markers ◽  
Ca 15.3

It has been widely demonstrated that patients diagnosed with chronic heart failure present high levels of circulating neurohormones and inflammation markers which can secondarily induce an increase of the level of tumor markers such as CA 125, AFP, CEA, CA 15.3 or CA 19-9. This is a literature review regarding the benefits of determination of tumor markers serum levels in cases presenting chronic heart failure.

Sign in / Sign up

Export Citation Format

Share Document